Aldosteronism and Resistant Hypertension
Resistant hypertension (RHTN) is defined as blood pressure (BP) that remains uncontrolled in spite of intake of ≥3 antihypertensive medications, ideally prescribed at optimal doses and one of which is a diuretic. The incidence of primary aldosteronism (PA) in patients with RHTN is estimated in prosp...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.4061/2011/837817 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564232593342464 |
|---|---|
| author | Maria Czarina Acelajado David A. Calhoun |
| author_facet | Maria Czarina Acelajado David A. Calhoun |
| author_sort | Maria Czarina Acelajado |
| collection | DOAJ |
| description | Resistant hypertension (RHTN) is defined as blood pressure (BP) that remains uncontrolled in spite of intake of ≥3 antihypertensive medications, ideally prescribed at optimal doses and one of which is a diuretic. The incidence of primary aldosteronism (PA) in patients with RHTN is estimated in prospective studies to be 14 to 23%, which is higher than in the general hypertensive population. Patients with PA are at an increased cardiovascular risk, as shown by higher rates of stroke, myocardial infarction, and arrhythmias compared to hypertensive individuals without PA. Likewise, RHTN is associated with adverse cardiovascular outcomes, and the contribution of PA to this increased risk is undetermined. Similar to PA, obstructive sleep apnea (OSA) is closely associated with RHTN, and a causal link between PA, OSA, and RHTN remains to be elucidated. The addition of MR antagonists to the antihypertensive regimen in patients with RHTN produces a profound BP-lowering effect, and this effect is seen in patients with or without biochemical evidence of PA, highlighting the role of relative aldosterone excess in driving treatment resistance in this group of patients. |
| format | Article |
| id | doaj-art-f4932bd88b6e4d088f827e450158fc4b |
| institution | Kabale University |
| issn | 2090-0392 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-f4932bd88b6e4d088f827e450158fc4b2025-02-03T01:11:31ZengWileyInternational Journal of Hypertension2090-03922011-01-01201110.4061/2011/837817837817Aldosteronism and Resistant HypertensionMaria Czarina Acelajado0David A. Calhoun1Vascular Biology and Hypertension Program, University of Alabama at Birmingham, CH19, Room 115, 1530 3rd Avenue South, Birmingham, AL 35294-2041, USAVascular Biology and Hypertension Program, University of Alabama at Birmingham, CH19, Room 115, 1530 3rd Avenue South, Birmingham, AL 35294-2041, USAResistant hypertension (RHTN) is defined as blood pressure (BP) that remains uncontrolled in spite of intake of ≥3 antihypertensive medications, ideally prescribed at optimal doses and one of which is a diuretic. The incidence of primary aldosteronism (PA) in patients with RHTN is estimated in prospective studies to be 14 to 23%, which is higher than in the general hypertensive population. Patients with PA are at an increased cardiovascular risk, as shown by higher rates of stroke, myocardial infarction, and arrhythmias compared to hypertensive individuals without PA. Likewise, RHTN is associated with adverse cardiovascular outcomes, and the contribution of PA to this increased risk is undetermined. Similar to PA, obstructive sleep apnea (OSA) is closely associated with RHTN, and a causal link between PA, OSA, and RHTN remains to be elucidated. The addition of MR antagonists to the antihypertensive regimen in patients with RHTN produces a profound BP-lowering effect, and this effect is seen in patients with or without biochemical evidence of PA, highlighting the role of relative aldosterone excess in driving treatment resistance in this group of patients.http://dx.doi.org/10.4061/2011/837817 |
| spellingShingle | Maria Czarina Acelajado David A. Calhoun Aldosteronism and Resistant Hypertension International Journal of Hypertension |
| title | Aldosteronism and Resistant Hypertension |
| title_full | Aldosteronism and Resistant Hypertension |
| title_fullStr | Aldosteronism and Resistant Hypertension |
| title_full_unstemmed | Aldosteronism and Resistant Hypertension |
| title_short | Aldosteronism and Resistant Hypertension |
| title_sort | aldosteronism and resistant hypertension |
| url | http://dx.doi.org/10.4061/2011/837817 |
| work_keys_str_mv | AT mariaczarinaacelajado aldosteronismandresistanthypertension AT davidacalhoun aldosteronismandresistanthypertension |